a2b530
Non-Small Cell Squamous Lung Carcinoma
Explore 53 assets in Non-Small Cell Squamous Lung Carcinoma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
A2 Biotherapeutics Inc.
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05736731CT.gov A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Squamous Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| a2b530 (this asset) | A2 Biotherapeutics Inc. | P1/2 | CC · 47 |
| Carboplatin | Gruppo Oncologico Italiano di Ricerca Clinica | P3 | BBB |
| Pembrolizumab | Shanghai Henlius Biotech | P3 | BB |
| Serplulimab | Shanghai Henlius Biotech | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Gruppo Oncologico Italiano di Ricerca Clinica | P3 | BB |
| Docetaxel | Shanghai Henlius Biotech | P3 | BB |
| Tislelizumab | BeOne Medicines | P3 | BB |
| Catequentinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P3 | BB |
| Olaparib | Merck Sharp & Dohme LLC | P3 | BB |
+42 more in the Non-Small Cell Squamous Lung Carcinoma cohort
Other indications for a2b530
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P1/2 | CC · 43 |
| Malignant Pancreatic Neoplasm | — | P1/2 | CC · 43 |
| Colorectal Adenocarcinoma | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. a2b530 in Non-Small Cell Squamous Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/a2b530-non-small-cell-squamous-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →